We are proud to announce that our Moxidectin project has achieved a new milestone:
The New Drug Application (NDA) of Moxidectin for treatment of the orphan disease river blindness has been approved by the US FDA this week. The product was developed by Medicines Development for Global Health, an independently funded biopharmaceutical company that focuses exclusively on neglected diseases, while the Moxidectin API is supplied by Pharmax and manufactured by Livzon Group. The successful approval of the New Drug Application represents a joint success of MDGH, Pharmax and Livzon who have been working hard together for years, and the first approval of moxidectin for use in humans.
MDGH received funding for this project from the Global Health Investment Fund, and plans to supply Moxidectin to those in need, mainly in Africa. We believe the new moxidectin product will bring health benefits to people in both developing and developed world.